EUVIMEDEUVIMED entdecken
Crossref

A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia

Alexandre Bazinet iD, Alex Bataller iD, Tapan Kadia iD, Naval Daver iD, Nicholas J Short iD, Musa Yilmaz, Koji Sasaki iD, Courtney D DiNardo iD, Gautam M Borthakur, Ghayas Issa, Ian Bouligny iD, Sherry Pierce und 3 weitere

Cancer · 2025

DOI: 10.1002/cncr.35813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Alexandre Bazinet und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: The University of Texas MD Anderson Cancer Center Support Grant, The University of Texas MD Anderson Cancer Center Myelodysplastic Syndrome/Acute Myeloid Leukemia Moon Shot.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

FMS‐like tyrosine kinase 3 ( FLT3 ) mutations, either internal tandem duplications ( FLT3 ‐ITD) or tyrosine kinase domain ( FLT3 ‐TKD), are common in acute myeloid leukemia (AML). FLT3 ‐ITD confers an adverse prognosis.

Methods

The authors performed a retrospective study including 619 patients to evaluate outcomes in newly diagnosed FLT3 ‐mutated AML across treatment regimens.

Results

In patients with FLT3 ‐ITD–mutated AML who received intensive chemotherapy (IC), the addition of a FLT3 inhibitor (FLT3i) was associated with trends toward improved relapse‐free survival (median 32.3 vs. 14.3 months with vs. without a FLT3i; p = .055) and overall survival (OS; 35.5 vs. 18.9 months with vs. without a FLT3i; p = .098). In patients with FLT3 ‐ITD mutations who received low‐intensity (LIT) regimens, triplets (LIT plus a FLT3i plus venetoclax) were associated with significantly longer OS (19.1 months) compared with those who received other treatment combinations (11.2 months with LIT alone, 9.2 months with LIT plus FLT3i, and 10.3 months with LIT plus venetoclax). Patients with FLT3 ‐ITD plus NPM1 co‐mutations who received any therapy had a trend toward improved OS (2‐year OS: 47% vs. 33%; p = .087). The FLT3 ‐ITD allelic ratio; IDH1 , IDH2 , WT1 , RUNX1 , and myelodysplastic syndrome‐related mutations; and adverse cytogenetics had no significant impact on OS. In landmark analyses, allogeneic stem cell transplantation was associated with a trend toward improved OS in patients with FLT3 ‐ITD mutations who received IC (52.6 vs. 22.7 months with versus without allogeneic stem cell transplantation; p = .076) and a marked improvement in OS in those who received LIT (38.6 vs. 14.0 months with vs. without allogeneic stem cell transplantation; p < .0001).

Conclusions

A FLT3i and allogeneic stem cell transplantation are key treatment modalities for patients who have FLT3 ‐mutated AML. LIT‐based triplets are promising in IC‐ineligible patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedNucleophosminYoung AdultTreatment OutcomeHematopoietic Stem Cell TransplantationProtein Kinase InhibitorsAdolescentAged, 80 and overSulfonamidesPrognosisBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

FLT3 inhibitorsFMS‐like tyrosine kinase 3 (FLT3)acute myeloid leukemiavenetoclax

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanNucleophosminNPM1 protein, humanProtein Kinase InhibitorsSulfonamidesvenetoclaxBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Alexandre Bazinet, Alex Bataller, Tapan Kadia, Naval Daver, Nicholas J Short, Koji Sasaki, Courtney D DiNardo, Ian Bouligny, Guillermo Garcia-Manero, Hagop M Kantarjian

Förderung

  • The University of Texas MD Anderson Cancer Center Support Grant
  • The University of Texas MD Anderson Cancer Center Myelodysplastic Syndrome/Acute Myeloid Leukemia Moon Shot

Zitieren

APA

Bazinet, A., Bataller, A., Kadia, T., Daver, N., Short, N. J., Yilmaz, M., Sasaki, K., DiNardo, C. D., Borthakur, G. M., Issa, G., Bouligny, I., Pierce, S., Garcia-Manero, G., Ravandi, F., & Kantarjian, H. M. (2025). A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.35813

Vancouver

Bazinet A, Bataller A, Kadia T, Daver N, Short NJ, Yilmaz M, et al. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.35813

BibTeX
@article{Bazinet2025,
  author = {Bazinet, Alexandre and Bataller, Alex and Kadia, Tapan and Daver, Naval and Short, Nicholas J and Yilmaz, Musa and Sasaki, Koji and DiNardo, Courtney D and Borthakur, Gautam M and Issa, Ghayas and Bouligny, Ian and Pierce, Sherry and Garcia-Manero, Guillermo and Ravandi, Farhad and Kantarjian, Hagop M},
  title = {A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35813}
}
Kostenlos starten →